Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020

Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenue for the second quarter of 2020 as well as for the first half of 2020.

Revenue for the second quarter of 2020 (unaudited)

In K€	Q2 2020	Q1 2020	Q2 2019	Q1 2019
Revenue	13.4	23.5	31.9	5.2
Of which licenses	-	-	-
Of which services	13.4	23.5	31.9	5.2

Revenue for the six months ended June 30^th, 2020 (unaudited)

In K€	Six Months Ended June 30, 2020	Six Months Ended June 30, 2019
Revenue	36.9	37.1
Of which licenses	-	-
Of which services	36.9	37.1

Activity and results

Nanobiotix’s revenue for the second quarter 2020 and for the first half of 2020 amounted to €13.4k and €36.9k respectively.

Most of the revenue generated by the Company during these periods result from the cross-charge to its partner, PharmaEngine, of shared external contract research organization costs pursuant to the license and collaboration agreement.